Premium
Prognostic capacity of Systemic Inflammation Response Index (SIRI) in patients with head and neck squamous cell carcinoma
Author(s) -
Valero Cristina,
Pardo Laura,
Sansa Aina,
Garcia Lorenzo Jacinto,
López Montserrat,
Quer Miquel,
León Xavier
Publication year - 2020
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.26010
Subject(s) - medicine , head and neck squamous cell carcinoma , oncology , systemic inflammation , head and neck , basal cell , inflammation , biomarker , head and neck cancer , cancer , surgery , biochemistry , chemistry
Background Inflammation and immune evasion are associated with carcinogenesis. Systemic Inflammation Response Index (SIRI) has been proposed as a pretreatment peripheral blood biomarker. The aim of this study is to analyze its prognostic capacity in head and neck squamous cell carcinomas (HNSCC). Methods We performed a retrospective study in 824 patients with HNSCC. SIRI was calculated by neutrophils*monocytes/lymphocytes. Using a recursive‐partitioning analysis considering disease‐specific survival (DSS) as dependent variable, three categories were defined according to SIRI value. Results Males, patients with history of toxic consumption, oropharyngeal or hypopharyngeal tumors, and advanced tumors had a significantly higher SIRI value. As SIRI increased, a significant decrease in DSS was observed. In a multivariable analysis, SIRI was an independent predictor of DSS. Moreover, SIRI was a significant predictor of local, regional, and distant recurrence‐free survival. Conclusions SIRI has independent prognostic capacity in HNSCC. Patients with higher SIRI have a significant decrease in DSS.